Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOC Biocept (BIOC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Biocept Stock (NASDAQ:BIOC) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Biocept alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.43▼$1.6752-Week Range N/AVolume751,400 shsAverage Volume764,067 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Stock News HeadlinesFoundation Gives $2M to Set Up Margaret Faye Wilson Endowment at Salk InstituteMay 24, 2024 | msn.comWicklow Foundation Gives $2 Million to Establish Margaret Faye Wilson Endowment at Salk InstituteMay 23, 2024 | msn.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)Liquid Biopsy Market Worth $11.3 billion | MarketsandMarkets.May 8, 2024 | finanznachrichten.deAkron residents could see water and sewer rate increases over federally mandated projectsMay 2, 2024 | msn.comPlus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 6, 2024 | finanznachrichten.deCircular Genomics brings on 2 leadership hires following $8.3M raiseFebruary 27, 2024 | bizjournals.comCircular Genomics Strengthens Leadership Team with Key Commercial and Research HiresFebruary 26, 2024 | finance.yahoo.comSee More Headlines BIOC Stock Analysis - Frequently Asked Questions How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) announced its earnings results on Monday, November, 15th. The medical research company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. When did Biocept's stock split? Biocept shares reverse split before market open on Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biocept investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Vaxart (VXRT), NIO (NIO) and iBio (IBIO). Company Calendar Last Earnings11/15/2021Today10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees50Year Founded1993Profitability EPS (Most Recent Fiscal Year)($58.4549) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,090,000.00 Net MarginsN/A Pretax Margin-564.02% Return on Equity-468.87% Return on Assets-118.41% Debt Debt-to-Equity Ratio2.88 Current Ratio1.81 Quick Ratio1.70 Sales & Book Value Annual Sales$25.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$15.60 per share Price / BookN/AMiscellaneous Outstanding Shares2,630,000Free Float2,584,000Market Cap$1.14 million OptionableNot Optionable Beta0.69 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:BIOC) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biocept With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.